Fig 1 Survival curves according to MZL subtype: (A) OS and (B) PFS. MZL, marginal zone lymphoma; NMZL, nodal MZL; OS, overall survival; PFS, progression-free survival; SMZL, splenic MZL. The median Rw ...

The FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) patients who have received two prior therapies. MZL is an ...